#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3220	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2615	366.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1700	1700	C	503	C,T	424,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	3220	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2615	366.4	0	HET	.	.	.	A37T,C	.	37	37	A	553	553	A	459	A,T,C	327,86,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4832	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3932	367.1	0	.	n	.	0	T695C	SNP	695	695	T	1253	1253	C	390	C	319	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4832	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3932	367.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1895	1895	A	441	A,G	380,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4832	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3932	367.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2529	2529	C	414	C,G,A	350,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4832	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3932	367.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3155	3155	T	401	T,G,A	334,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4832	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3932	367.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2603	2603	A	441	A	381	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	528	folP	852	852	100.0	folP.l6.c17.ctg.1	2118	74.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1327	1329	AGC	128;129;131	A;G;C,G	100;105;104,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1082	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3937	82.4	1	SNP	p	S91F	0	.	.	271	273	TCC	854	856	TCC	94;94;94	T;C;C	75;75;76	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1082	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3937	82.4	1	SNP	p	D95N	0	.	.	283	285	GAC	866	868	GAC	96;95;94	G;A;C	80;78;77	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1082	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3937	82.4	1	SNP	p	D95G	0	.	.	283	285	GAC	866	868	GAC	96;95;94	G;A;C	80;78;77	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	452	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1680	80.6	0	.	p	.	0	A39T	NONSYN	115	117	GCC	614	616	ACC	116;116;116	A;C;C	101;99;102	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	452	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1680	80.6	0	.	p	.	0	R44H	NONSYN	130	132	CGC	629	631	CAC	122;122;122	C,T;A;C	104,1;104;105	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	452	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1680	80.6	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	812	814	CAC	120;121;119	C;A;C,A	103;105;100,1	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	452	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1680	80.6	1	SNP	p	G45D	0	.	.	133	135	GGC	632	634	GGC	121;121;121	G;G;C	104;100;107	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	304	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1438	63.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1146	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3303	103.8	1	SNP	p	D86N	0	.	.	256	258	GAC	751	753	GAC	111;109;109	G;A;C	88;88;93	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1146	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3303	103.8	1	SNP	p	S87I	0	.	.	259	261	AGT	754	756	AGT	108;108;107	A,C;G;T	84,1;90;86	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1146	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3303	103.8	1	SNP	p	S87W	0	.	.	259	261	AGT	754	756	AGT	108;108;107	A,C;G;T	84,1;90;86	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1146	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3303	103.8	1	SNP	p	S87R	0	.	.	259	261	AGT	754	756	AGT	108;108;107	A,C;G;T	84,1;90;86	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1146	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3303	103.8	1	SNP	p	S88P	0	.	.	262	264	TCC	757	759	TCC	107;109;109	T;C,A;C	87;88,1;88	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	970	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3103	93.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1852	1854	GGC	137;136;136	G;G;C,G	117;112;108,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1515	1517	GCA	112;112;116	G;C;A	90;88;92	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1518	1520	ATC	116;116;118	A;T;C,A	89;90;94,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1530	1532	GTG	119;119;119	G;T,A;G	97;94,1;94	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1530	1532	GTG	119;119;119	G;T,A;G	97;94,1;94	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2034	2036	ACC	81;81;81	A;C;C	70;69;69	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2088	2090	GCG	85;84;83	G;C;G	69;65;64	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2088	2090	GCG	85;84;83	G;C;G	69;65;64	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2211	2213	GGC	78;78;78	G;G;C	67;69;68	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2220	2222	GGC	79;79;78	G,A;G;C	70,1;68;70	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	736	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	75.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2238	2240	CCG	79;79;77	C;C;G	66;67;64	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1050	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3427	91.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1711	1713	CTG	108;110;111	C;T;G,T	88;88;88,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	608	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2164	84.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	762	762	C	111	C	93	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	562	564	GGA	127;126;126	G;G;A	107;107;110	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	0	.	p	.	0	G50N	NONSYN	148	150	GGC	568	570	AAC	125;125;124	A;A;C	110;110;108	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	823	825	CTT	112;111;111	C;T;T,C	97;96;93,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	847	849	GGA	113;113;112	G;G;A	95;97;97	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	0	.	p	.	0	D171G	NONSYN	511	513	GAT	931	933	GGT	101;99;98	G;G;T	83;85;82	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	985	987	AGC	108;108;108	A;G;C,A	94;92;94,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1051	1051	T	107	T,C	92,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	1	SNP	p	G120K	0	.	.	358	360	GGT	778	780	GGT	120;120;120	G;G,T;T	108;103,1;102	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	1	SNP	p	A121D	0	.	.	361	363	GCC	781	783	GCC	121;120;120	G;C;C	105;104;102	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	590	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1845	94.1	1	SNP	p	A121N	0	.	.	361	363	GCC	781	783	GCC	121;120;120	G;C;C	105;104;102	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2110	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5373	117.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2242	2244	AAT	129;130;132	A;A;T	111;109;112	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	346	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1313	78.7	1	SNP	p	V57M	1	.	.	169	171	ATG	667	669	ATG	134;134;135	A;T;G	112;112;112	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
